NO20072035L - Memantin for behandling av adferdsforstyrrelser hos barn - Google Patents
Memantin for behandling av adferdsforstyrrelser hos barnInfo
- Publication number
- NO20072035L NO20072035L NO20072035A NO20072035A NO20072035L NO 20072035 L NO20072035 L NO 20072035L NO 20072035 A NO20072035 A NO 20072035A NO 20072035 A NO20072035 A NO 20072035A NO 20072035 L NO20072035 L NO 20072035L
- Authority
- NO
- Norway
- Prior art keywords
- memantine
- children
- treatment
- behavioral disorders
- disorder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61260004P | 2004-09-23 | 2004-09-23 | |
PCT/US2005/034199 WO2006034465A1 (fr) | 2004-09-23 | 2005-09-23 | Memantine pour le traitement des troubles du comportement de l'enfant |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20072035L true NO20072035L (no) | 2007-06-13 |
Family
ID=35445934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20072035A NO20072035L (no) | 2004-09-23 | 2007-04-20 | Memantin for behandling av adferdsforstyrrelser hos barn |
Country Status (16)
Country | Link |
---|---|
US (2) | US20060079582A1 (fr) |
EP (1) | EP1799224A1 (fr) |
JP (1) | JP2008514620A (fr) |
KR (1) | KR20070046185A (fr) |
CN (1) | CN101374525A (fr) |
AR (1) | AR052643A1 (fr) |
AU (1) | AU2005286672B2 (fr) |
BR (1) | BRPI0515560A (fr) |
CA (1) | CA2578953A1 (fr) |
EA (1) | EA012036B1 (fr) |
IL (1) | IL182105A0 (fr) |
MX (1) | MX2007003267A (fr) |
NO (1) | NO20072035L (fr) |
TW (1) | TW200626160A (fr) |
WO (1) | WO2006034465A1 (fr) |
ZA (1) | ZA200702130B (fr) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7456224B2 (en) | 2004-04-05 | 2008-11-25 | Forest Laboratories Holdings, Ltd. | Method for treating autism |
EP2040676A2 (fr) * | 2006-07-06 | 2009-04-01 | Forest Laboratories, Inc. | Formulations à dissolution orale de mémantine |
RU2326660C1 (ru) * | 2007-03-14 | 2008-06-20 | Закрытое акционерное общество "Биологические исследования и системы" | Пероральный лекарственный препарат мемантин (варианты) и способ его получения (варианты) |
WO2009004440A2 (fr) * | 2007-06-29 | 2009-01-08 | Orchid Chemicals & Pharmaceuticals Limited | Compositions à dissolution rapide de chlorhydrate de mémantine |
US20090247644A1 (en) * | 2008-03-28 | 2009-10-01 | Forest Laboratories Holdings Limited | Memantine formulations |
EP2138173A1 (fr) | 2008-06-26 | 2009-12-30 | Merz Pharma GmbH & Co.KGaA | Compositions pharmaceutiques comportant des dérivés d'aminoadamantane |
EP2201950B1 (fr) * | 2008-12-08 | 2016-11-16 | Biocodex | Composés et procédés pour le traitement de troubles du spectre autistique |
IT1396556B1 (it) * | 2009-02-11 | 2012-12-14 | Serra | Uso di memantina per il trattamento di disturbi dell umore |
NO3034079T3 (fr) | 2010-11-15 | 2018-06-09 | ||
RU2488388C1 (ru) * | 2012-05-24 | 2013-07-27 | Ооо "Валента Интеллект" | Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств |
US9242009B2 (en) | 2012-07-17 | 2016-01-26 | The General Hospital Corporation | Compositions and methods to treat neurodegenerative diseases |
UA107653U (uk) * | 2012-10-01 | 2016-06-24 | Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" | Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів |
KR101424514B1 (ko) * | 2013-01-02 | 2014-07-31 | 건국대학교 산학협력단 | 선천성 발프로산 노출 증후군 치료제로서의 메만틴의 용도 |
EP2948135B1 (fr) * | 2013-01-25 | 2019-01-02 | Case Western Reserve University | Compositions et méthodes de traitement de troubles envahissants du développement |
WO2014153180A1 (fr) * | 2013-03-14 | 2014-09-25 | Michela Gallagher | Procédés et compositions pour améliorer la fonction cognitive |
MX2016007808A (es) | 2013-12-20 | 2016-09-07 | Agenebio Inc | Derivados de benzodiazepina, composiciones, y metodos para tratar el deterioro congnitivo. |
CA2986485A1 (fr) * | 2015-05-22 | 2016-12-01 | Arizona Board Of Regents On Behalf Of Arizona State University | Procedes pour le traitement d'un trouble du spectre de l'autisme et de symptomes associes |
CN113264939A (zh) | 2015-06-19 | 2021-08-17 | 艾吉因生物股份有限公司 | 用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法 |
RU2746000C2 (ru) | 2016-08-24 | 2021-04-05 | Зодженикс Интернэшнл Лимитед | Состав для ингибирования образования агонистов 5-ht2b и способы его применения |
US11505555B2 (en) | 2016-12-19 | 2022-11-22 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
AU2018309710A1 (en) | 2017-08-01 | 2020-02-27 | Stuart A. Lipton | Methods and compositions for treating neurological conditions |
US20190091179A1 (en) * | 2017-09-26 | 2019-03-28 | Zogenix International Limited | Congnitive function with fenfluramine |
FR3075038B1 (fr) | 2017-12-15 | 2020-03-06 | Melchior Material And Life Science France | Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete |
WO2019246300A1 (fr) | 2018-06-19 | 2019-12-26 | Agenebio, Inc. | Dérivés de benzodiazépine, compositions, et méthodes de traitement de déficience cognitive |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES413944A1 (es) * | 1972-04-20 | 1976-06-01 | Merz & Co | Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5. |
HU169986B (fr) * | 1972-12-07 | 1977-03-28 | ||
DE2856393C2 (de) * | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
US5366738A (en) * | 1982-07-29 | 1994-11-22 | Merck & Co., Inc. | Controlled release drug dispersion delivery device |
US6024983A (en) * | 1986-10-24 | 2000-02-15 | Southern Research Institute | Composition for delivering bioactive agents for immune response and its preparation |
US4849222A (en) * | 1987-03-24 | 1989-07-18 | The Procter & Gamble Company | Mixtures for treating hypercholesterolemia |
JP2670680B2 (ja) * | 1988-02-24 | 1997-10-29 | 株式会社ビーエムジー | 生理活性物質含有ポリ乳酸系微小球およびその製造法 |
ATE94384T1 (de) * | 1989-04-14 | 1993-10-15 | Merz & Co Gmbh & Co | Verwendung von adamantan-derivaten zur praevention und behandlung der cerebralen ischaemie. |
US4994467A (en) * | 1989-05-31 | 1991-02-19 | Zimmerman Andrew W | Treating autism and other developmental disorders in children with NMDA receptor antagonists |
US6057373A (en) * | 1997-05-22 | 2000-05-02 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists |
US6326226B1 (en) * | 1997-07-15 | 2001-12-04 | Lg. Philips Lcd Co., Ltd. | Method of crystallizing an amorphous film |
EP1047436B1 (fr) * | 1998-01-13 | 2009-10-21 | Synchroneuron, LLC | N-acétylhomotaurinates pour utilisation dans le traitement de la hyperkinésie |
AU4517201A (en) * | 1999-12-08 | 2001-06-18 | Vanderbilt University | Modulation of in vivo glutamine and glycine levels in the treatment of autism |
US6727231B1 (en) * | 2000-10-12 | 2004-04-27 | Repligen Corporation | Uridine therapy for patients with elevated purine levels |
JP2005518411A (ja) * | 2002-01-16 | 2005-06-23 | エンド ファーマシューティカルズ インコーポレーテッド | 中枢神経系の障害を治療する製薬組成物及び方法 |
EP1523309A2 (fr) * | 2002-07-19 | 2005-04-20 | Khalid Iqbal | Antagonistes du recepteur nmda et leur utilisation pour inhiber l'hyperphosphorylation de la proteine associee aux microtubules tau |
TW200531680A (en) * | 2004-03-03 | 2005-10-01 | Merz Pharma Gmbh & Co Kgaa | Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease |
-
2005
- 2005-09-23 AU AU2005286672A patent/AU2005286672B2/en not_active Ceased
- 2005-09-23 EA EA200700708A patent/EA012036B1/ru not_active IP Right Cessation
- 2005-09-23 CN CNA2005800321868A patent/CN101374525A/zh active Pending
- 2005-09-23 JP JP2007533663A patent/JP2008514620A/ja active Pending
- 2005-09-23 BR BRPI0515560-6A patent/BRPI0515560A/pt not_active IP Right Cessation
- 2005-09-23 TW TW094133147A patent/TW200626160A/zh unknown
- 2005-09-23 KR KR1020077006537A patent/KR20070046185A/ko not_active Application Discontinuation
- 2005-09-23 CA CA002578953A patent/CA2578953A1/fr not_active Abandoned
- 2005-09-23 WO PCT/US2005/034199 patent/WO2006034465A1/fr active Application Filing
- 2005-09-23 EP EP05802627A patent/EP1799224A1/fr not_active Withdrawn
- 2005-09-23 US US11/234,764 patent/US20060079582A1/en not_active Abandoned
- 2005-09-23 MX MX2007003267A patent/MX2007003267A/es unknown
- 2005-09-26 AR ARP050103986A patent/AR052643A1/es not_active Application Discontinuation
-
2007
- 2007-03-13 ZA ZA200702130A patent/ZA200702130B/xx unknown
- 2007-03-21 IL IL182105A patent/IL182105A0/en unknown
- 2007-04-20 NO NO20072035A patent/NO20072035L/no not_active Application Discontinuation
-
2009
- 2009-10-30 US US12/609,105 patent/US20100081723A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2578953A1 (fr) | 2006-03-30 |
CN101374525A (zh) | 2009-02-25 |
EP1799224A1 (fr) | 2007-06-27 |
EA012036B1 (ru) | 2009-06-30 |
BRPI0515560A (pt) | 2008-07-29 |
MX2007003267A (es) | 2007-05-23 |
US20060079582A1 (en) | 2006-04-13 |
AU2005286672A1 (en) | 2006-03-30 |
AU2005286672B2 (en) | 2009-03-12 |
ZA200702130B (en) | 2008-09-25 |
EA200700708A1 (ru) | 2007-08-31 |
IL182105A0 (en) | 2007-07-24 |
KR20070046185A (ko) | 2007-05-02 |
TW200626160A (en) | 2006-08-01 |
US20100081723A1 (en) | 2010-04-01 |
WO2006034465A1 (fr) | 2006-03-30 |
WO2006034465A8 (fr) | 2006-06-08 |
AR052643A1 (es) | 2007-03-28 |
JP2008514620A (ja) | 2008-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20072035L (no) | Memantin for behandling av adferdsforstyrrelser hos barn | |
WO2005037203A3 (fr) | Procedes et reactifs pour le traitement de troubles inflammatoires | |
CY1121135T1 (el) | Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος | |
MX2008006076A (es) | Metodos, composiciones y kits para el tratamiento de condiciones medicas. | |
NO20080246L (no) | Anti-IGF1R-antistofformuleringer | |
WO2007103373A3 (fr) | Compositions et procédés pour le traitement de troubles immunoinflammatoires | |
BR112014018592A2 (pt) | composição e método para o diagnóstico e tratamento de doenças associadas à degeneração de neuritos | |
WO2007100777A3 (fr) | Méthodes pour le traitement du tdah et de troubles apparentés | |
DOP2009000269A (es) | Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos | |
BRPI0510224A (pt) | métodos de prevenção de doença autoimunológica e artigo industrializado | |
WO2008097277A3 (fr) | Expression tcl1 dans la leucémie lymphocytaire chronique (llc) régulée par mir-29 et mir-181 | |
WO2008005534A3 (fr) | Formulations à dissolution orale de mémantine | |
EA201001322A1 (ru) | Вакцины против хламидиоза | |
BRPI0907135B8 (pt) | uso de um anticorpo antagonista anti-cgrp para a prevenção e/ou tratamento de dor de câncer crônica | |
EA200701995A1 (ru) | Способы уменьшения кальцификации | |
WO2006014638A3 (fr) | Anticorps anti-oligomeres reticules de la proteine $g(b)-amyloide | |
PL2341344T3 (pl) | Sposób diagnozowania wielotorbielowatości nerek | |
WO2010059242A3 (fr) | Compositions diagnostiques de maladie neurodégénérative et procédés d'utilisation | |
WO2006059252A3 (fr) | Procedes et compositions fluorees pour le traitement de maladies associees aux amyloides | |
ATE454465T1 (de) | In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie | |
CY1110620T1 (el) | Μεθοδος θεραπειας οξειας παραρρινοκολπιτιδας | |
WO2009032172A3 (fr) | Compositions de platine en tant que traitement pour des cancers liés à un transporteur de cations organiques | |
EP1899726A4 (fr) | Méthodes de diagnostic et de traitement des événements cérébrovasculaires reposant sur des peptides nr2 | |
CY1116166T1 (el) | Νεα μεθοδος για την αντιμετωπιση λοιμωξεων απο η.pylori | |
SG165413A1 (en) | Pecam-1 genotype |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |